July 8, 2025 · Form 4 insider transaction
Heffernan Michael Thomas bought 45,000 shares of enGene Therapeutics Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
This option vests at 1/3 on each of the first, second and third anniversaries of Mr. Heffernan's date of appointment to the Board, which was July 8, 2025.